![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Texas Drugmaker Lands Warning Letter Over GMP Violations
Texas Drugmaker Lands Warning Letter Over GMP Violations
June 27, 2016
The FDA issued a warning letter to a Texas drugmaker, citing four GMP violations related to sterility.
A March 2015 inspection found Stafford-Texas based S.R. Burzynski Manufacturing facility neglected to establish procedures to prevent microbiological contamination and failed to use appropriate equipment for manufacturing, processing and holding sterile products.
For example, the facility had not established procedures to ensure the facility’s manual aseptic process is capable of yielding sterile units. Additionally, the facility’s arrangement permitted low quality air to enter the facility’s aseptic processing environment.
Upcoming Events
-
21Oct